Headache News and Research

Latest Headache News and Research

Researchers perform systematic review to identify best treatments for cancer-related depression

Depression is common in cancer, up to half of all patients facing the disease experience depressive symptoms, ranging from mild to severe. When depression co-exists with cancer, patients may be at an increased risk of death from cancer and from suicide.

27 Jun 2014

Tips to protect children from summer bugs

Mike Gittelman, MD, Co-Director, Comprehensive Children's Injury Center and the experts at Cincinnati Children's Hospital Medical Center want to make sure that families and children stay safe while playing outdoors this summer.

26 Jun 2014

Chronic migraine significantly impacts family relationships and activities

A web-based study of 994 men and women with chronic migraine found that the condition significantly impacts family relationships and activities, including cancelled vacation plans and reduced quality time with partners and children.

25 Jun 2014

Forest Laboratories reports positive results from three Phase III trials of vilazodone for GAD treatment

Forest Laboratories, Inc. today announced positive topline results from three Phase III trials evaluating the efficacy, safety and tolerability of vilazodone in adult patients with generalized anxiety disorder (GAD).

24 Jun 2014

Cubist Pharmaceuticals' SIVEXTRO receives FDA approval for treatment of ABSSSI

Cubist Pharmaceuticals, Inc. announced today the U.S. Food and Drug Administration approved SIVEXTRO (tedizolid phosphate) for the treatment of adult acute bacterial skin and skin structure infections (ABSSSI).

21 Jun 2014

Osteoarthritis may be treated with stem cell mobilization therapy

Researchers in Taiwan have found that peripheral blood stem cells can be "mobilized" by injection of a special preparation of granulocyte colony-stimulating factor (G-CSF) into rats that modeled osteoarthritis (OA).

20 Jun 2014

Alkermes reports data from aripiprazole lauroxil phase 3 clinical trial for treatment of schizophrenia

Alkermes plc today announced the presentation of data from its phase 3 clinical trial of aripiprazole lauroxil, an investigational drug candidate in development for schizophrenia, at the American Society of Clinical Psychopharmacology Annual Meeting in Hollywood, Fla.

18 Jun 2014

Alexion announces that FDA grants ODD to Soliris for Myasthenia Gravis treatment

Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to Soliris® (eculizumab) for the treatment of patients with Myasthenia Gravis (MG), a rare, debilitating neurologic disorder caused by uncontrolled complement activation.

17 Jun 2014

Combining 2 smoking cessation therapies more effective for highly nicotine-dependent smokers

Combining two smoking cessation therapies is more effective than using just one for male and highly nicotine-dependent smokers who weren't initially helped by the nicotine patch, according to researchers at Duke Medicine.

17 Jun 2014

Cranial ultrasound has greater sensitivity than temporal artery biopsy in diagnosis of GCA

A new study presented for the first time today at the European League Against Rheumatism Annual Congress (EULAR 2014), shows that cranial ultrasound has a greater sensitivity than temporal artery biopsy,* and a comparable specificity in the diagnosis of Giant Cell Arteritis (GCA).

13 Jun 2014

Osteoarthritis patients treated with SoluMatrix meloxicam report greater pain relief

Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today will present Phase 3 results that showed osteoarthritis (OA) patients treated with investigational SoluMatrix meloxicam 5 mg and 10 mg, a low dose nonsteroidal anti-inflammatory drug (NSAID), reported significantly greater pain relief compared with placebo.

12 Jun 2014

Janssen, Viiv Healthcare to develop single tablet regimen for maintenance treatment of HIV

Janssen R&D Ireland Ltd announced today that they have entered into a collaboration with ViiV Healthcare to develop and commercialize a new single tablet regimen containing Janssen's Non-Nucleoside Reverse Transcriptase Inhibitor rilpivirine (marketed as EDURANT®) and ViiV's Integrase Inhibitor dolutegravir(marketed as TIVICAY®) as the sole active ingredients for the maintenance treatment of people living with Human Immunodeficiency Virus (HIV).

12 Jun 2014

Auxilium and Prasco introduce authorized generic version of Testim

Auxilium Pharmaceuticals, Inc., a fully integrated specialty biopharmaceutical company, today announced that it has partnered with Prasco, LLC ("Prasco") to introduce an Authorized Generic version of Testim® (testosterone gel).

11 Jun 2014

Celgene: OTEZLA phase III study for psoriatic arthritis meets primary endpoint

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced results of additional analyses from the phase III clinical trials of OTEZLA, the Company's oral, selective inhibitor of phosphodiesterase 4 (PDE4).

11 Jun 2014

1% of adults experience headaches associated with sexual activity, shows report

About 1 percent of adults report they have experienced headaches associated with sexual activity, and that such headaches can be severe.

10 Jun 2014

electroCore's non-invasive vagus nerve stimulation therapy reduces cluster headache attacks

In a multi-center, randomized, trial across Europe, electroCore's non-invasive vagus nerve stimulation (nVNS) therapy was found to meet its primary endpoint of statistical significance in reducing the number of cluster headache attacks when compared with the standard of care.

10 Jun 2014

BioDelivery Sciences receives approval of NDA for BUNAVAIL from FDA

BioDelivery Sciences International, Inc. received approval of the New Drug Application (NDA) for BUNAVAIL™ (buprenorphine and naloxone) buccal film (CIII) from the U.S. Food and Drug Administration (FDA).

9 Jun 2014

U.S. Preventive Services Task Force recommends hepatitis B screening for high risk individuals

A simple blood test can detect if a person is one of the two billion people worldwide infected with hepatitis B. And now the U.S. Preventive Services Task Force recommends that all teens and adults who are high risk for hepatitis B get screened for the infection.

6 Jun 2014

New report focuses attention on wait times at El Paso VA facility

The document, which was commissioned by Rep. Beto O'Rourke, D-Texas, found wait times as long as 71 days for veterans who sought mental health treatment at the facility. This finding was very different from official statistics.

6 Jun 2014

Merck enrolls first patient in reformulated raltegravir Phase 3 trial for treatment of HIV-1 infection

Merck, known as MSD outside the United States and Canada, today announced that the first patient has been enrolled in the company's global Phase 3 clinical trial, ONCEMRK.

6 Jun 2014

Headache News and Research

Latest Headache News and Research

Researchers perform systematic review to identify best treatments for cancer-related depression

Tips to protect children from summer bugs

Chronic migraine significantly impacts family relationships and activities

Forest Laboratories reports positive results from three Phase III trials of vilazodone for GAD treatment

Cubist Pharmaceuticals' SIVEXTRO receives FDA approval for treatment of ABSSSI

Osteoarthritis may be treated with stem cell mobilization therapy

Alkermes reports data from aripiprazole lauroxil phase 3 clinical trial for treatment of schizophrenia

Alexion announces that FDA grants ODD to Soliris for Myasthenia Gravis treatment

Combining 2 smoking cessation therapies more effective for highly nicotine-dependent smokers

Cranial ultrasound has greater sensitivity than temporal artery biopsy in diagnosis of GCA

Osteoarthritis patients treated with SoluMatrix meloxicam report greater pain relief

Janssen, Viiv Healthcare to develop single tablet regimen for maintenance treatment of HIV

Auxilium and Prasco introduce authorized generic version of Testim

Celgene: OTEZLA phase III study for psoriatic arthritis meets primary endpoint

1% of adults experience headaches associated with sexual activity, shows report

electroCore's non-invasive vagus nerve stimulation therapy reduces cluster headache attacks

BioDelivery Sciences receives approval of NDA for BUNAVAIL from FDA

U.S. Preventive Services Task Force recommends hepatitis B screening for high risk individuals

New report focuses attention on wait times at El Paso VA facility

Merck enrolls first patient in reformulated raltegravir Phase 3 trial for treatment of HIV-1 infection

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Headache News and Research

Latest Headache News and Research

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in